LAVA Therapeutics NV

LVTX

NASDAQ. Currency in USD

6.75 +1.24 ( +22.50% )

Real time prices: December 01

Market Cap.
177.45M
Beta (5Y monthly)
-
Price/Earnings
-
EPS (TTM)
-1.06
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
90,094
1y Target Est.
17.31
Day's Range
5.52
-
6.81
52 Week's Range
2.28
-
7.89

Historical Summary

Performance
Share Buybacks

About LAVA Therapeutics NV

Sector
Healthcare
Industry
Biotechnology
Website
https://www.lavatherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
25.11M
Employees
55
Address
Yalelaan 60, Utrecht, Netherlands, 3584 CM
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Latest news

Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6%...
By Zacks Investment Research - 6 days ago

LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for...
By Zacks Investment Research - 2 weeks ago

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq:...
By GlobeNewswire Inc. - 2 weeks ago

Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know
Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know

LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for...
By Zacks Investment Research - 2 weeks ago

Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for...
By Zacks Investment Research - 2 weeks ago

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for...
By Zacks Investment Research - 3 weeks ago

Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates
Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for...
By Zacks Investment Research - 3 weeks ago

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq:...
By GlobeNewswire Inc. - 4 weeks ago